Page last updated: 2024-11-12

1,3-dioleoyl-2-palmitoylglycerol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1,3-dioleoyl-2-palmitoylglycerol : A triglyceride in which the acyl groups at positions 1 and 3 are specified as oleoyl while that at position 2 is specified as palmitoyl. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID13183955
CHEBI ID75846
SCHEMBL ID2575052
MeSH IDM0251175

Synonyms (37)

Synonym
1,3-dioleoyl-2-palmitoylglycerol
(2-hexadecanoyloxy-3-octadec-9-enoyloxypropyl) octadec-9-enoate
1716-07-0
1,3-di(cis-9-octadecenoyl)-2-hexadecanoylglycerol
tag(18:1/16:0/18:1)
triacylglycerol(18:1/16:0/18:1)
2-(palmitoyloxy)propane-1,3-diyl (9z,9'z)bis-octadec-9-enoate
CHEBI:75846
tg(18:1(9z)/16:0/18:1(9z))
tg(18:1/16:0/18:1)
tg[18:1(omega-9)/16:0/18:1(omega-9)]
2-(hexadecanoyloxy)propane-1,3-diyl (9z,9'z)bis-octadec-9-enoate
1,3-di-(9z)-octadecenoyl-2-hexadecanoylglycerol
SCHEMBL2575052
triglyceride opo,sn
1-oleo-2-palmito-3-olein
triglyceride opo
2-palmito-1,3-diolein
palmitin, 1,3-dioleo-2-
glycerol dioleate monopalmitate
9-octadecenoic acid (9z)-, 1,1'-(2-((1-oxohexadecyl)oxy)-1,3-propanediyl) ester
9-octadecenoic acid (9z)-, 2-((1-oxohexadecyl)oxy)-1,3-propanediyl ester
VLQ6P59TQY ,
1,3-di-(9z-octadecenoyl)-2-hexadecanoyl-sn-glycerol
glyceryl 2-palmitate-1,3-dioleate
unii-vlq6p59tqy
1,3-do-2pg
1-palmitoyl-2,3-dioleoylglycerol
1,3-dioleoylpalmitoylglycerol
1-(9z-octadecenoyl)-2-hexadecanoyl-3-(9z-octadecenoyl)-glycerol
1-oleoyl-2-palmitoyl-3-oleoyl-glycerol
Q27145593
[2-hexadecanoyloxy-3-[(z)-octadec-9-enoyl]oxypropyl] (z)-octadec-9-enoate
HY-N10372
CS-0437187
BP-29824
PD121726

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Optimum conditions could be attained with 6 min pretreatment time, 50% ultrasonic power, 3 s/9 s (work/pause) cycle of ultrasonic pulse, 1:8 PPP/OA molar ratio, 12% enzyme dosage and 50 °C temperature of."( Ultrasonic pretreatment in lipase-catalyzed synthesis of structured lipids with high 1,3-dioleoyl-2-palmitoylglycerol content.
Chen, H; Dong, XY; Liu, SL; Lv, X; Quek, SY; Wang, X; Wei, F; Wu, L; Zhong, J, 2015
)
0.64
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
triglycerideAny glyceride resulting from the condensation of all three hydroxy groups of glycerol (propane-1,2,3-triol) with fatty acids.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
Triacylglycerol Degradation TG(18:1(9Z)/16:0/18:1(9Z))512
De Novo Triacylglycerol Biosynthesis TG(18:1(9Z)/16:0/18:1(9Z))514

Research

Studies (21)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (14.29)18.2507
2000's2 (9.52)29.6817
2010's13 (61.90)24.3611
2020's3 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.56 (24.57)
Research Supply Index3.09 (2.92)
Research Growth Index5.01 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (23.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other21 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]